NCT07416604: A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- State
- Under way
- Phase
- Phase 3
- People
- 360 planned
- Started
- 27 Apr 2026
- Primary completion
- 29 Feb 2028
- Arms
- Main Study Treatment Period: NXT007 Prophylaxis, Open-Label Extension Period: NXT007 Prophylaxis
- Results
- None posted
- 18 Feb 2026: Trial registered
- 27 Apr 2026: Trial started